$XBI $91.70 | -1.64%
Covid Updates
$
Pipeline Updates
$PRVB -1.8% Provention Bio Announces Initiation of the Phase 2a PREVAIL-2 Study of PRV-3279 (CD32B × CD79 Bispecific DART® Molecule) in Systemic Lupus Erythematosus (SLE) source
$ASLN -5.0% ASLAN Pharmaceuticals Initiates Phase 2b Study of ASLAN004 (Eblasakimab) in Moderate-to-Severe Atopic Dermatitis source
$KURA -7.5% Kura Oncology Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 in Acute Myeloid Leukemia source
$RMTI -8.6% Rockwell Medical Announces Regulatory Approval of Triferic® Dialysate in South Korea source
$TPTX -1.7% Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Combination of Elzovantinib and Aumolertinib in EGFR Mutant Met-Amplified Non-Small Cell Lung Cancer source
$ONCY +7.7% Oncolytics Biotech® Provides Enrollment Update on Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium source
$OPK -1.6% Japan’s MHLW Approves Pfizer and OPKO’s NGENLA® (Somatrogon), a New Long-Acting Treatment for Pediatric Growth Hormone Deficiency source
$NUVB +4.9% Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-868 for the Treatment of Advanced Solid Tumors source
Business Updates
$BDSI +6.0% BioDelivery Sciences Expects 2021 Revenue at the High End of Full Year Guidance source
Posted by JM
Comments